EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling

References

• Baldys A, Gooz M, Morinelli TA, Lee MH, Raymond JRJr, Luttrell LM, Raymond JRSr. 2009. Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry. 48:1462–1473.
   Google Scholar
• Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. 1996. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 271:5251–5257.
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. 2006. EGF–ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol. 7:505–516.
   PubMed Web of Science ®Google Scholar
• Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, Gu H, Band V, Band H. 2003. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem. 278:28950–28960.
   PubMed Web of Science ®Google Scholar
• Eden ER, Huang F, Sorkin A, Futter CE. The role of EGF receptor ubiquitination in regulating its intracellular traffic. Traffic. 2011ressDOI101111/j1600-0854201101305x[Eubaheadofrt].
   Google Scholar
• Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP, Riese DJ2nd. 2010. EGFR signaling in breast cancer: Bad to the bone. Semin Cell Dev Biol. 21:951–960.
   Google Scholar
• Gilmore JL, Gallo RM, Riese DJ. 2006. The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. Biochem J. 396:79–88.
   PubMedGoogle Scholar
• Gilmore JL, Scott JA, Bouizar Z, Robling A, Pitfield SE, Riese DJ2nd, Foley J. 2008. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat. 110:493–505.
   PubMed Web of Science ®Google Scholar
• Grovdal LM, Stang E, Sorkin A, Madshus IH. 2004. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res. 300:388–395.
   PubMed Web of Science ®Google Scholar
• Hobbs SS, Cameron EM, Hammer RP, Le AT, Gallo RM, Blommel EN, Coffing SL, Chang H, Riese DJ2nd. 2004. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene. 23:883–893.
   PubMed Web of Science ®Google Scholar
• Johnson GR, Kannan B, Shoyab M, Stromberg K. 1993. Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells. J Biol Chem. 268:2924–2931.
   PubMedGoogle Scholar
• Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. 2007. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci. 120:3688–3699.
   Google Scholar
• Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gomez C, Paez de la Cadena M. 2007. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br J Cancer. 96:1569–1578.
   PubMed Web of Science ®Google Scholar
• Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 4:1029–1040.
   PubMed Web of Science ®Google Scholar
• Mill CP, Gettinger KL, Riese DJ2nd. 2011. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res. 317:392–404.
   Web of Science ®Google Scholar
• Morgenstern JP, Land H. 1990. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587–3596.
   PubMed Web of Science ®Google Scholar
• Penington DJ, Bryant I, Riese DJ2nd. 2002. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ. 13:247–256.
   PubMedGoogle Scholar
• Ravid T, Heidinger JM, Gee P, Khan EM, Goldkorn T. 2004. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem. 279:37153–37162.
   PubMedGoogle Scholar
• Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. 2008. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol. 19:73–80.
   PubMed Web of Science ®Google Scholar
• Riese DJ2nd, van Raaij TM, Plowman GD, Andrews GC, Stern DF. 1995. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol. 15:5770–5776.
   PubMed Web of Science ®Google Scholar
• Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grovdal L, Willumsen BM, van Deurs B. 2009. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic. 10:1115–1127.
   PubMed Web of Science ®Google Scholar
• Rotin D, Margolis B, Mohammadi M, Daly RJ, Daum G, Li N, Fischer EH, Burgess WH, Ullrich A, Schlessinger J. 1992. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: Identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. Embo J. 11:559–567.
   PubMedGoogle Scholar
• Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ. 1989. Structure and function of human amphiregulin: A member of the epidermal growth factor family. Science. 243:1074–1076.
   PubMed Web of Science ®Google Scholar
• Sorkin A, Goh LK. 2009. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 315:683–696.
   PubMed Web of Science ®Google Scholar
• Stern KA, Place TL, Lill NL. 2008. EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem J. 410:585–594.
   Google Scholar
• Suh PG, Park JI, Manzoli L, Cocco L, Peak JC, Katan M, Fukami K, Kataoka T, Yun S, Ryu SH. 2008. Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep. 41:415–434.
   PubMed Web of Science ®Google Scholar
• VanBrocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, Gilmore JL, Bryant I, Riese DJ2nd. 2005. Anilinodialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem. 48:7445–7456.
   Google Scholar
• van de Poll ML, van Rotterdam W, Gadellaa MM, Jacobs-Oomen S, van Zoelen EJ. 2005. Ligand depletion negatively controls the mitogenic activity of epidermal growth factor. Exp Cell Res. 304:630–641.
   Google Scholar
• Walker-Daniels J, Riese DJ2nd, Kinch MS. 2002. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res. 1:79–87.
   PubMed Web of Science ®Google Scholar
• Willmarth NE, Ethier SP. 2006. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem. 281:37728–37737.
   PubMed Web of Science ®Google Scholar
• Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ2nd, Ethier SP. 2009. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal. 21:212–219.
   PubMed Web of Science ®Google Scholar
• Wilson KJ, Mill CP, Cameron EM, Hobbs SS, Hammer RP, Riese DJ2nd. 2007. Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Commun. 364:351–357.
   PubMed Web of Science ®Google Scholar
• Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ2nd. 2009. Functional selectivity of EGF family peptide growth factors: Implications for cancer. Pharmacol Ther. 122:1–8.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Lindeman N, Homes AJ, Jackman DM, Zhao F, Rogers AM, Johnson BE, Janne PA. 2008. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res. 14:6963–6973.
   PubMed Web of Science ®Google Scholar